PL2173376T3 - Multimeryczne wieloepitopowe szczepionki przeciwko grypie - Google Patents

Multimeryczne wieloepitopowe szczepionki przeciwko grypie

Info

Publication number
PL2173376T3
PL2173376T3 PL08789738T PL08789738T PL2173376T3 PL 2173376 T3 PL2173376 T3 PL 2173376T3 PL 08789738 T PL08789738 T PL 08789738T PL 08789738 T PL08789738 T PL 08789738T PL 2173376 T3 PL2173376 T3 PL 2173376T3
Authority
PL
Poland
Prior art keywords
influenza vaccines
multimeric multiepitope
multiepitope influenza
multimeric
vaccines
Prior art date
Application number
PL08789738T
Other languages
English (en)
Inventor
Tamar Ben-Yedidia
Yossi Singer
Original Assignee
Biondvax Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biondvax Pharmaceuticals Ltd filed Critical Biondvax Pharmaceuticals Ltd
Publication of PL2173376T3 publication Critical patent/PL2173376T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL08789738T 2007-08-02 2008-08-03 Multimeryczne wieloepitopowe szczepionki przeciwko grypie PL2173376T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95349807P 2007-08-02 2007-08-02
PCT/IL2008/001062 WO2009016639A2 (en) 2007-08-02 2008-08-03 Multimeric multiepitope influenza vaccines
EP08789738.5A EP2173376B1 (en) 2007-08-02 2008-08-03 Multimeric multiepitope influenza vaccines

Publications (1)

Publication Number Publication Date
PL2173376T3 true PL2173376T3 (pl) 2015-08-31

Family

ID=40305020

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08789738T PL2173376T3 (pl) 2007-08-02 2008-08-03 Multimeryczne wieloepitopowe szczepionki przeciwko grypie

Country Status (17)

Country Link
US (2) US8747861B2 (pl)
EP (1) EP2173376B1 (pl)
JP (1) JP5654345B2 (pl)
KR (1) KR101580660B1 (pl)
CN (1) CN101795709B (pl)
AU (1) AU2008281384C1 (pl)
BR (1) BRPI0815008B8 (pl)
CA (1) CA2695399C (pl)
DK (1) DK2173376T3 (pl)
EA (1) EA017887B1 (pl)
ES (1) ES2539818T3 (pl)
HR (1) HRP20150479T1 (pl)
HU (1) HUE025149T2 (pl)
MX (1) MX2010001284A (pl)
PL (1) PL2173376T3 (pl)
PT (1) PT2173376E (pl)
WO (1) WO2009016639A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP3058954B1 (en) * 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
JP5805195B2 (ja) 2010-08-23 2015-11-04 カンステム バイオテック カンパニー リミテッド Ｎｏｄ２アゴニストで処理した幹細胞またはその培養物を含む免疫疾患および炎症性疾患の予防および治療用の薬学的組成物
EP2678361A4 (en) * 2011-02-21 2015-06-03 Vaxinnate Corp COMPOSITIONS WITH IMPROVED IMMUNOGENICITY AND / OR REDUCED REACTIVITY AND METHOD OF USE THEREOF
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
JP6113155B2 (ja) * 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すｈ１ｎ１インフルエンザの抗原
ES2490915B1 (es) * 2011-09-12 2015-09-17 Laboratorios Del Dr. Esteve, S.A. Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos
WO2013112916A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
HK1203983A1 (en) * 2012-04-02 2015-11-06 Folia Biotech Inc. Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
CN103055311B (zh) * 2012-12-28 2014-05-21 中山大学 一种传染性喉气管炎粘膜疫苗及其制备方法和应用
WO2014108515A1 (en) * 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
CN106163553B (zh) * 2014-04-03 2021-07-23 彼昂德瓦克斯医药有限公司 多聚体-多表位流感多肽的组合物及其产生
KR102748840B1 (ko) * 2016-02-03 2025-01-02 씨지 디스커버리, 인코포레이티드 이종 에피토프 및/또는 성숙 절단 부위를 갖는 인플루엔자 헤마글루티닌 조성물
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
JP2020515283A (ja) 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド インフルエンザワクチン
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
JP7320601B2 (ja) * 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
EP3986447A4 (en) * 2019-06-18 2023-08-16 Citranvi Biosciences, LLC RATIONALLY MANIPULATED CARRIER PROTEINS FOR VACCINES
US20240277831A1 (en) * 2020-02-14 2024-08-22 University Of Washington Polypeptides, compositions, and their use to treat or limit development of an infection
US11149286B1 (en) 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
JP2023542341A (ja) * 2020-09-21 2023-10-06 エスアールアイ インターナショナル 標的化された抗原送達システム及びその使用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4539205A (en) 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9201139D0 (en) 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
IL107025A0 (en) 1992-09-16 1993-12-28 Univ Tennessee Res Corp Recombinant multivalent m protein vaccine
US5683695A (en) 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US7063967B2 (en) 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
WO1998052573A1 (en) 1997-05-20 1998-11-26 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1999007839A2 (en) 1997-08-05 1999-02-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ATE215385T1 (de) 1997-12-16 2002-04-15 Chiron Corp Verwendung von mikropartikeln mit submikron öl/wasser emulsionen
GB9807805D0 (en) 1998-04-09 1998-06-10 Smithkline Beecham Biolog Vaccine
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
HK1039072A1 (zh) 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
US6828416B1 (en) 1998-08-21 2004-12-07 The United States Of America As Represented By The Department Of Health And Human Services Recombinant multivalent malarial vaccine against Plasmodium falciparum
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
WO2001021189A1 (en) 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
AU1075001A (en) 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6843781B2 (en) 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
DK1294892T3 (da) 2000-06-23 2008-01-28 Wyeth Corp Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er)
WO2004003145A2 (en) 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
BRPI0407877A (pt) 2003-03-07 2006-03-01 Merck & Co Inc conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
JP5094407B2 (ja) * 2004-12-16 2012-12-12 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ Ｙｅｒｓｉｎｉａｐｅｓｔｉｓの免疫療法におけるフラジェリンの使用
WO2006069262A2 (en) 2004-12-21 2006-06-29 Vaxinnate Corporation Compositions of influenza viral proteins and methods of use thereof
CA2594612A1 (en) 2005-01-19 2006-07-27 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
US20090104216A1 (en) * 2005-06-01 2009-04-23 Variation Biotechnologies, Inc. Peptide-Based Influenza Vaccine Formulation
US7260958B2 (en) 2005-09-14 2007-08-28 National Taipei University Technology Electrohydrodynamic condenser device
EP1945253A2 (en) 2005-11-04 2008-07-23 Novartis Vaccines and Diagnostics S.r.l. Adminstration routes for priming/boosting with influenza vaccines
ES2385842T3 (es) * 2005-12-06 2012-08-01 Yeda Research And Development Co., Ltd. Vacuna mejorada contra la gripe
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
EP2069376A4 (en) * 2006-07-21 2013-10-16 Pharmexa Inc INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
CA2697049A1 (en) 2007-08-21 2009-02-26 Dynavax Technologies Corporation Composition and methods of making and using influenza proteins

Also Published As

Publication number Publication date
AU2008281384A1 (en) 2009-02-05
EA201070219A1 (ru) 2010-08-30
DK2173376T3 (en) 2015-06-29
BRPI0815008B1 (pt) 2019-11-19
US20110182974A1 (en) 2011-07-28
HRP20150479T1 (hr) 2015-07-17
AU2008281384B2 (en) 2012-02-16
BRPI0815008B8 (pt) 2021-05-25
CA2695399A1 (en) 2009-02-05
EA017887B1 (ru) 2013-03-29
WO2009016639A2 (en) 2009-02-05
JP2010535026A (ja) 2010-11-18
CN101795709A (zh) 2010-08-04
WO2009016639A3 (en) 2009-04-30
ES2539818T3 (es) 2015-07-06
US20140286982A1 (en) 2014-09-25
PT2173376E (pt) 2015-07-30
AU2008281384C1 (en) 2012-08-16
US8747861B2 (en) 2014-06-10
HK1142809A1 (en) 2010-12-17
EP2173376B1 (en) 2015-03-25
US9353159B2 (en) 2016-05-31
MX2010001284A (es) 2010-08-31
KR20100045473A (ko) 2010-05-03
EP2173376A2 (en) 2010-04-14
JP5654345B2 (ja) 2015-01-14
KR101580660B1 (ko) 2015-12-28
CA2695399C (en) 2017-10-17
HUE025149T2 (hu) 2016-01-28
CN101795709B (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
PT2173376E (pt) Vacinas de influenza multiepitópicas multiméricas
SI2185191T1 (sl) Cepiva proti influenci z majhnimi dodatki
IL196024A0 (en) Influenza vaccine
IL199663A0 (en) Vaccine
IL201782A0 (en) Vaccine
GB0717911D0 (en) Vaccine
GB0711858D0 (en) Vaccine
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
IL206307A0 (en) Vaccine
AP2010005166A0 (en) Vaccines
EP1998814A4 (en) NEW VACCINES AGAINST INFLUENZA M2
PT2422810E (pt) Vacina da gripe
ZA201100962B (en) Influenza vaccines
GB0710538D0 (en) Vaccine
GB0700135D0 (en) Vaccine
ZA201003851B (en) Vaccine
EP2240199A4 (en) INFLUENZA VACCINES
ZA200900062B (en) Influenza vaccine
GB0709373D0 (en) BCG-based anti-atheroma vaccine
PL383661A1 (pl) Podpora
GB0623865D0 (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine
GB0619090D0 (en) Influenza vaccine
GB0618195D0 (en) Influenza vaccine
GB0623218D0 (en) Influenza vaccine